Atara Biotherapeutics
Tracked across 13 events · 146 articles · First seen May 15, 2025 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: Atara Biotherapeutics is facing a class action lawsuit for allegedly making false and misleading statements about its growth potential, leading to a significant drop in its stock price.
May 21, 2025 · 7 articles
Business
Impact: Atara Biotherapeutics is facing a class action lawsuit for alleged securities fraud, which led to a significant drop in its stock price.
May 15, 2025 · 6 articles
Business
Impact: Atara Biotherapeutics is the defendant in a class action lawsuit alleging false and misleading statements regarding its business operations and prospects, which could lead to financial penalties and reputational damage.
May 19, 2025 · 6 articles
Business
Impact: Atara Biotherapeutics is facing a securities fraud class action lawsuit for allegedly misleading investors about the demand for its melanoma treatment, Amtagvi, and its authorized treatment centers. This led to a significant drop in its stock price.
May 19, 2025 · 20 articles
Regulatory
Impact: Atara Biotherapeutics, Inc. is facing a federal securities class action lawsuit due to alleged false and misleading statements regarding its growth potential and product demand, which led to a significant stock price decline.
May 18, 2025 · 6 articles
Business
Multiple law firms, including the Law Offices of Howard G. Smith, the The Law Offices of Frank R. Cruz, and Glancy Prongay & Murray LLP, have announced opportunities for investors to lead a securities fraud…
Impact: Atara Biotherapeutics is the defendant in a securities fraud class action lawsuit, facing allegations of misleading investors about manufacturing issues and regulatory prospects of its drug tabelecleucel.
May 01, 2026 · 6 articles
Business
Rosen Law Firm has filed a class action lawsuit against Atara Biotherapeutics, alleging that the company made false and misleading statements to investors between May 20, 2024, and January 9, 2026. The lawsuit claims that…
Impact: Atara Biotherapeutics is the defendant in a class action lawsuit alleging misleading statements regarding its tabelecleucel Biologics License Application and manufacturing issues. This event negatively impacts its stock price and reputation.
Apr 01, 2026 · 58 articles
Business
Pomerantz LLP has filed a class action lawsuit against Atara Biotherapeutics and certain officers in the United States — United States District Court for the Northern District of California. The lawsuit alleges that Atara Biotherapeutics…
Impact: Atara Biotherapeutics is the defendant in a class action lawsuit alleging false and misleading statements regarding its business, operations, and prospects, specifically concerning the regulatory approval of its lead product candidate, tabelecleucel. Its stock price experienced significant declines following FDA decisions.
May 01, 2026 · 6 articles
Regulatory
The The Schall Law Firm has initiated a class action lawsuit against Atara Biotherapeutics, alleging violations of securities laws. The lawsuit claims that Atara Biotherapeutics made false and misleading statements to investors between May 20,…
Impact: Atara Biotherapeutics is the defendant in a class action lawsuit for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its drug tabelecleucel, leading to investor losses.
May 01, 2026 · 6 articles
Tech
Impact: Atara Biotherapeutics, co-founded by Fred Ramsdell, is actively developing therapies based on the discoveries of regulatory T cells, with support from Regeneron, indicating potential for future market clearance.
Oct 06, 2025 · 6 articles
Tech
Impact: Fred Ramsdell is a scientific adviser for Atara Biotherapeutics, which is mentioned as his affiliation.
Oct 06, 2025 · 6 articles
100
Atara Biotherapeutics made misleading statementsAtara Biotherapeutics...
100
Levi & Korsinsky notifies investors of lawsuit Atara BiotherapeuticsAtara Biotherapeutics...
100
Pomerantz LLP filed class action lawsuit Atara BiotherapeuticsAtara Biotherapeutics...
100
Robbins LLP filed class action Atara BiotherapeuticsAtara Biotherapeutics...
100
The Schall Law Firm filed class action lawsuit Atara BiotherapeuticsAtara Biotherapeutics...
95
Rosen Law Firm filed class action lawsuit Atara BiotherapeuticsAtara Biotherapeutics...
95
United States — Food and Drug Administration issued Complete Response Letter Atara BiotherapeuticsAtara Biotherapeutics...
91
Atara Biotherapeutics made misleading statementsAtara Biotherapeutics...
90
Atara Biotherapeutics made misleading statementsAtara Biotherapeutics...
90
United States — Food and Drug Administration issued Complete Response Letter Atara BiotherapeuticsAtara Biotherapeutics...
90
United States — Food and Drug Administration issued Complete Response Letter Atara BiotherapeuticsAtara Biotherapeutics...
80
The Law Offices of Frank R. Cruz announced lawsuit opportunity Atara BiotherapeuticsAtara Biotherapeutics...
80
Glancy Prongay & Murray announced lawsuit opportunity Atara BiotherapeuticsAtara Biotherapeutics...
70
Atara Biotherapeutics submitted Biologics License Application United States — Food and Drug AdministrationAtara Biotherapeutics...
62
Atara Biotherapeutics submitted Biologics License Application United States — Food and Drug AdministrationAtara Biotherapeutics...
NEWSDESK
Track Atara Biotherapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard